Journal of Medicinal Chemistry p. 1613 - 1633 (2016)
Update date:2022-08-15
Topics:
Reddy, Damodara N.
Ballante, Flavio
Chuang, Timothy
Pirolli, Adele
Marrocco, Biagina
Marshall, Garland R.
Selective inhibition of KDAC isoforms while maintaining potency remains a challenge. Using the largazole macrocyclic depsipeptide structure as a starting point for developing new KDACIs with increased selectivity, a combination of four different simplified largazole analogue (SLA) scaffolds with diverse zinc-binding groups (for a total of 60 compounds) were designed, synthesized, and evaluated against class I KDACs 1, 3, and 8, and class II KDAC6. Experimental evidence as well as molecular docking poses converged to establish the cyclic tetrapeptides (CTPs) as the primary determinant of both potency and selectivity by influencing the correct alignment of the zinc-binding group in the KDAC active site, providing a further basis for developing new KDACIs of higher isoform selectivity and potency.
View MoreJi'nan Orgachem Pharmaceutical Co.,Ltd
Contact:+86-531-82687810
Address:Jinan
Contact:+86-310-7092106
Address:Quzhou Modern & New Industrial Park, Handan, Hebei 057250, China
Jinan Baozhao Pharmaceutical Co., Ltd
Contact:0086-531-86397156 82371858 82371868
Address:Huaneng Road, Jinan, Shandong ,China
Tianjin Realet Chemical Technology Co.,Ltd.
website:http://www.realetchem.com
Contact:+86-022-58788819
Address:shuanggang industrial park
Jinan Yijialian Economic and Trade Development Co., Ltd.
Contact:+86 0531-66729596
Address:jinan
Doi:10.1246/bcsj.65.3288
(1992)Doi:10.1021/jm00054a005
(1993)Doi:10.3390/ijms19103050
(2018)Doi:10.1016/S0040-4039(99)00389-5
(1999)Doi:10.1016/S0957-4166(97)00614-9
(1998)Doi:10.1002/chem.201600229
(2016)